Combination therapies of porcupine inhibition with ruxolitinib, ibrutinib or belumosudil in murine sclerodermatous GvHD.
Hong X, Xiao Y, Xu L, Shen L, Neelagar R, Devakumar V, Trinh-Minh T, Liang M, Rius Rigau A, Zhang Y, Li YN, Dees C, Györfi AH, Wolff D, Herr W, Schett G, Distler JHW, Matei AE.
Hong X, et al. Among authors: xu l.
Blood Adv. 2025 Jan 7:bloodadvances.2024014387. doi: 10.1182/bloodadvances.2024014387. Online ahead of print.
Blood Adv. 2025.
PMID: 39775728
No abstract available.